

33,700 Results Any time ▾

[HER2 status in breast cancer determined by IHC and FISH ...](#)

<https://pubmed.ncbi.nlm.nih.gov/15757204>

All cases described by IHC as 0/1+ were also HER2-negative by FISH. IHC is well-established method of assessing HER2 status in breast cancer. Nonetheless, a group of cases described as 2+ should be additionally examined using FISH. The results obtained by the latter method are more reliable. In order to improve accuracy and gain the highest ...

Cited by: 17 Author: Anna Mrozkowiak, Wojciech P Olszewski, ...
Publish Year: 2004

[Influence of Neoadjuvant Chemotherapy on HER2/neu ...](#)

<https://www.sciencedirect.com/science/article/pii/S1526820912002157>

Feb 01, 2013 · The PathVysion HER2 DNA Probe Kit (Vysis Inc, Downers Grove, IL) was used to detect the HER2/neu gene via FISH in 32 pairs of formalin-fixed paraffin-embedded breast cancer tissue specimens in which the HER2/neu IHC scores changed, except for those in which the score changed only from 4+ to 0 or from 0 to 4+. Assay procedure was performed according to the PathVysion

Search Tools

Turn off Hover Translation (关闭取词)

5,470 Results Any time ▾

Predictors of pathological complete response to ...

<https://www.nature.com/articles/s41379-021-00738-5>

Feb 01, 2021 · In the current study, 22% of HER2-positive tumours became HER2-negative by IHC and FISH following neoadjuvant treatment, the majority (74%) HER2 IHC 2+/HER2 amplified tumours.

Cited by: 2 Author: Ayaka Katayama, Ayaka Katayama, Isla...

Publish Year: 2021

Influence of Neoadjuvant Chemotherapy on HER2/neu ...

<https://www.sciencedirect.com/science/article/pii/S1526820912002157>



09 Jul 2021 10:16AM 2312 words • 2 matches • 2 sources

iThenticate 64989_Auto_Edited.docx Quoted Excluded Bibliography Excluded 3%

Name of Journal: *World Journal of Clinical Cases*
Manuscript NO: 64989
Manuscript Type: CASE REPORT

HER2 negative by IHC (1+) but positive by FISH after neoadjuvant chemotherapy in breast cancer: A case report and review of literature

Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen

Abstract
BACKGROUND
As the most common cancer in women, breast cancer is the leading cause of death. Most

Match Overview

1	Internet 14 words www.kksko.org	1%
2	Internet 13 words crawled on 28-Jul-2020 breast-cancer-research.biomedcentral.com	1%

Page 1 of 3

Text-Only Report

国内版

国际版

HER2 turns to positive after neoadjuvant chemotherapy in breast c



ALL

IMAGES

VIDEOS

71,500 Results

Any time ▾

[Her-2 positive mucinous carcinoma breast cancer, case report](#)

<https://pubmed.ncbi.nlm.nih.gov/29291541>

Case summary: A 48-year-old female presented with a lump in her right breast and after a biopsy, it was diagnosed as mucinous carcinoma in the core biopsy and surgical resection, with positive hormone receptors and HER2 positive (3+) in 100% of the tumor cells. She was treated with neoadjuvant chemotherapy based on trastuzumab and pertuzumab ...

Cited by: 7

Author: Ilean Garcia Hernandez, Mauricio Canava...

Publish Year: 2018

[Neoadjuvant treatment for HER2-positive breast cancer](#)

<https://pubmed.ncbi.nlm.nih.gov/32527117>

Neoadjuvant therapy has become a standard clinical practice to downsize the tumor and increase the breast-conserving rate. The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast cancer ...

Cited by: 1

Author: Masahiro Takada, Masakazu Toi

Publish Year: 2020

PEOPLE ALSO ASK

Which is the best neoadjuvant for HER2 positive breast cancer? ▾

Which is better Trastuzumab or neoadjuvant for breast cancer? ▾

How does T-DM1 work for HER2 positive breast cancer? ▾

How is neoadjuvant chemotherapy used to judge its effectiveness? ▾

Feedback

[De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg ...](#)

<https://www.clinicaltrials.gov/ct2/show/NCT04675827> ▾

Dec 19, 2020 · De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade: Estimated Study Start Date : June 2021: Estimated Primary Completion Date : June 2023: Estimated Study Completion Date :